Jak skontaktować się z centrum
Centrum HCP
Zatrudniając około 14.100 XNUMX pracowników, UKE jest trzecim co do wielkości pracodawcą w Wolnym i Hanzeatyckim Mieście Hamburg.
Badania w UKE
Badania są ważnym warunkiem postępu w diagnostyce i terapii. Badania UKE kładą nacisk na neuronauki, badania układu krążenia, badania nad opieką, onkologię, a także infekcje i stany zapalne. Inne potencjalne obszary działalności UKE to badania z zakresu obrazowania molekularnego i biologii szkieletu.
Kontakt
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Zespół
Pr Martin Spitzer
Niemcy
Dr Johannes Birtel
Niemcy
Badania kliniczne
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
European Disease Registry on Retinopathy of Prematurity (ROP)
Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion
A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema Conditions
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma (DecodeVRL)
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER)